SCREENING & PREVENTION OF CERVICAL CANCER

LATEST GUIDELINES



APRNworld

SCREENING AND PREVENTION OF CERVICAL CANCER: LATEST GUIDELILNES

ANCC ACCREDITED NCPD HOURS: 2hrs

TARGET AUDIENCE: RN/APRN

NEED ASSESSMENT

Every two minutes, a woman dies from cervical cancer, contributing to over 350,000 deaths globally each year. This disease disproportionately affects younger women, particularly in low- and middle-income countries, where access to screening and treatment remains limited. Despite significant advancements in understanding HPV-induced carcinogenesis, clinical outcomes have remained largely unchanged in many parts of the world over the past decades.

While much is known about the role of high-risk HPV types (particularly HPV 16 and 18) in cervical cancer development, gaps in prevention, screening, and treatment continue to hinder progress. However, with increased global efforts including improved vaccination programs, expanded screening initiatives, and advancements in therapeutics- there is immense potential to drastically reduce mortality rates from this preventable and treatable disease.

This article highlights the urgent need to address challenges in prevention, screening, and care delivery while proposing actionable solutions. With focused global efforts such as increasing HPV vaccination rates, expanding screening access, and ensuring equitable treatment availability a significant reduction in cervical cancer mortality can be achieved in a relatively short timeframe.

By leveraging scientific advancements and strengthening healthcare infrastructure, the world is well-positioned to move closer to WHO's goal of eliminating cervical cancer as a public health problem by 2030.

OBJECTIVES

- Discuss the epidemiology of cervical cancer in the US and risk factors for the development of the disease
- Review the anatomy of the cervix and the pathophysiology leading to the development of cervical precancer and cancer
- Explain the Importance of Cervical Cancer Staging
- Review the History of Cervical Cancer Staging
- Summarize Current Guidelines for Cervical Cancer Screening
- Describe the Role of Ultrasound in Cervical Cancer Diagnosis
- Discuss Cervical Cancer Mortality Rates and Their Implications
- Understanding about Neuroendocrine Neoplasia's (NENs)
- Define Key Strategies for Cervical Cancer Prevention
- Elaborate the management and preventive strategies and incorporate nursing interventions.

GOALS

This article aims to provide a comprehensive review of the latest guidelines for cervical cancer screening and prevention. It highlights the most recent recommendations from leading health organizations.

Additionally, the article focuses on current best practices for primary care providers in performing and interpreting the Pap smear test, emphasizing its role in early detection, risk assessment, and clinical decision-making.

INTRODUCTION

Cervical cancer is the **fourth most common cancer in women worldwide**, with approximately **660,000 new cases and 350,000 deaths in 2022**, disproportionately affecting low- and middle-income countries due to limited screening and HPV vaccination. **Persistent infection with high-risk Human Papillomavirus (HPV), particularly HPV 16 and 18, is the primary cause**, with key risk factors including **early sexual activity, multiple sexual partners, history of STIs, long-term contraceptive use, high parity, immunosuppression, and smoking**.

Recognized as a **preventable disease**, cervical cancer screening and HPV vaccination are critical in reducing mortality and incidence. **WHO's Global Strategy to Accelerate the Elimination of Cervical Cancer** aims for **90% HPV vaccination coverage, 70% screening by ages 35 and 45, and 90%**

treatment access for cervical disease by 2030. Current screening guidelines recommend **HPV DNA testing every 5 years for women aged 30–65, co-testing(Pap + HPV) every 5 years, and Pap smear alone every 3 years for women 21–29**. Despite the proven benefits, screening uptake is hindered by **lack of awareness, cultural stigma, financial barriers, and healthcare provider attitudes**. While **ultrasound is not the primary screening tool**, it assists in **tumour size assessment, lymph node evaluation, and guiding biopsies**, with MRI and CT remaining the preferred imaging modalities for staging.

Strengthening global screening programs, increasing HPV vaccination rates, and addressing barriers to care are essential steps toward eliminating cervical cancer as a public health threat and achieving a significant decline in mortality within the coming decades. [1, Rank 5]

EPIDEMIOLOGY IN THE US

Approximately 0.7% of females (1 in 159) will be diagnosed with cervical cancer during their lifetime. According to the National Cancer Institute (NCI, 2023a), cervical cancer's annual age-adjusted incidence rate is 7.7 per 100,000 women. Racial disparities in cervical cancer are large. Hispanic women have the highest incidence (9.9 per 100,000), followed by non-Hispanic Black (NHB; 8.8 per 100,000) and non-Hispanic American Indian/Alaska Native women (AI/AN; 8.8 per 100,000). Non-Hispanic Asian/Pacific Islanders (API) have the lowest incidence (6.1 per 100,000). NHB women are 30% more likely to develop and 60% more likely to die from the disease than non-Hispanic White women (NHW; ACS, 2022, 2023a; Spencer et al., 2023). The median age at diagnosis is 50, and the disease occurs most frequently in women aged 35 to 44 (24.1%), followed by those aged 45 to 54 (21.6%). While 20% of cases occur in women over 65, cervical cancer rarely develops in those who have maintained compliance with recommended screenings (ACS, 2021c, 2023a, 2023b).

The 5-year survival rate of localized cervical cancer (i.e., cancer that has not spread outside of the cervix or uterus) is 92%, declining to 17% for those with distant metastases (i.e., cancer spread to distant organs or body parts). NHB women are more likely to be diagnosed at advanced stages of the disease, reducing their 5-year survival rate to 56% compared to 67% in NHW women (ACS, 2022, 2023a, 2023c). While survival has improved since the 1970s for most cancer types, it has remained relatively stagnant for cervical cancers; this is attributed to the lack of significant treatment advances for

patients with recurrent and metastatic disease. Furthermore, nearly 90% of women who die from cervical cancer have inadequate access to prevention, screening, and treatment (World Health Organization [WHO], 2022).







RISK FACTORS



Risk factors for cervical cancer include HPV infection, tobacco use, early onset of sexual activity, multiple sexual partners, and HIV infection. Predominantly transmitted through sexual contact, HPV is the chief risk factor for cervical cancer, leading to nearly 99% of diagnoses. Tobacco use is the only nonsexual behaviour associated with cervical dysplasia (i.e., abnormal cell growth on the cervix) and cancer. Smokers are at least twice as likely as non-smokers to be diagnosed with cervical cancer. Research has demonstrated that among women with HPV infections, those who smoke have a significantly higher viral load on the

cervix, heightening the risk of cancer development (Fang et al., 2018; Truth Initiative, 2019). Early sexual activity and multiple sexual partners (especially those with numerous partners) increase the risk of HPV exposure. Immunocompromised people—such as those with HIV, transplant recipients, cancer patients, and those receiving immunosuppressive medications—are at higher risk for acquiring HPV.

ANATOMY OF THE CERVIX

The **cervix** is the lower, cylindrical part of the uterus that extends into the upper portion of the vagina. It serves as a passageway between the uterus and the vaginal canal, playing an essential role in menstruation, fertility, and childbirth. The cervix is divided into two main regions: the **ectocervix**, which projects into the vagina, and the **endocervical canal**, which connects the vaginal environment to the uterine cavity. These areas are lined by different types of epithelium—**stratified squamous epithelium** on the ectocervix and **columnar epithelium** within the endocervical canal.

The **transformation zone**, where these two types of epithelial cells meet (known as the squamocolumnar junction), is the most clinically significant area in relation to cervical cancer. This zone undergoes constant cellular turnover and is especially vulnerable to infection with **high-risk human papillomavirus (HPV)** types, which are responsible for the majority of cervical cancer cases. Nearly all **squamous cell carcinomas** of the cervix originate here, making it a primary target during cervical cancer screening procedures such as Pap smears and HPV testing.

Cervical cancer can spread locally and regionally due to its anatomical position. Locally, it may invade the vagina, uterus, bladder, rectum, or pelvic sidewalls. Through the lymphatic system, it commonly spreads to the **parametrial**, **obturator**, **internal and external iliac**, **presacral**, and **para-aortic lymph nodes**. This anatomical knowledge is crucial in staging the disease and determining treatment options.

Understanding cervical anatomy is also essential during diagnostic and therapeutic procedures. Accurate sampling of the transformation zone is critical for detecting precancerous changes.

Furthermore, the cervix's structure influences surgical decisions in procedures such as **cone biopsy**, **loop electrosurgical excision procedure (LEEP)**, and **radical hysterectomy**. Thus, a detailed knowledge of cervical anatomy is foundational to the effective prevention, diagnosis, and management of cervical cancer.



PATHOPHYSIOLOGY OF CERVICAL CANCER: A NURSING PERSPECTIVE

HPV infection may clear or may progress to intraepithelial lesion. This lesion may exist in the non-invasive stage for as long as 20 years & shed abnormal cells that can be detected on cytologic examination by Papanicolaou smear screening

Cervical cancer is a **preventable yet life-threatening malignancy**, primarily caused by **persistent infection with high-risk human papillomavirus (HPV), especially types 16 and 18**. As nurses play a crucial role in **patient education, early detection, and care**, understanding the **disease process, risk factors, and prevention strategies** is essential for providing **evidence-based care**.

Pathophysiological Process

1. **HPV Infection & Cellular Transformation:**
   a. HPV enters the **basal epithelial cells** of the cervix, particularly in the **transformation zone** where the squamous and columnar epithelium meet.
   b. If the immune system fails to clear the virus, persistent infection leads to **genetic alterations and uncontrolled cellular growth**.
2. **Dysplasia (Precancerous Changes):**
   a. Cellular changes progress from **Cervical Intraepithelial Neoplasia (CIN)**, categorized as:
      - **CIN 1 (Mild Dysplasia):** Low-grade lesion, often reversible.
      - **CIN 2 (Moderate Dysplasia):** Higher risk of progression to cancer.
      - **CIN 3 (Severe Dysplasia/Carcinoma in Situ):** Considered a precancerous stage.





3. **Invasive Cervical Cancer:**
   a. When abnormal cells invade the **basement membrane**, it becomes invasive cancer.
   b. Common types include **squamous cell carcinoma (70-80%)** and **adenocarcinoma (10-25%)**.
   c. The tumor spreads through:
      - **Direct invasion** (uterus, vagina, bladder, rectum).
      - **Lymphatic system** (pelvic and para-aortic lymph nodes).
      - **Bloodstream** (lungs, liver, bones).

THE IMPORTANCE OF STAGING OF CERVIX CANCER

Cervical cancer remains one of the **leading causes of cancer-related deaths in women**, with significant disparities in diagnosis, treatment, and survival outcomes. Mortality rates are **18 times higher in low- and middle-income countries (LMICs) compared to high-income nations**, primarily due to the **lack of organized screening programs, limited access to HPV vaccination, and inadequate healthcare infrastructure**. Each year, cervical cancer accounts for **more than 530,000 new cases and over 270,000 deaths worldwide**, with the highest burden in regions where **screening and early detection efforts are insufficient**.

Despite advances in medical research, **progress in early detection and treatment has been slow**. However, studies have shown **improved survival rates** with the addition of **cisplatin-based chemotherapy to radiation therapy**, particularly in locally advanced disease. Notably, cervical cancer can be effectively treated even without advanced technology when **timely diagnosis and access to essential therapies are available**. Historical data from nearly a century ago demonstrated **75% survival rates in early-stage cervical cancer**, long before the advent of modern imaging techniques.

One of the key challenges in cervical cancer management is its status as a **clinically staged disease**, largely due to **limited access to imaging in resource-constrained settings**. Unlike other malignancies where cross-sectional imaging is standard for staging, cervical cancer remains **clinically staged** to accommodate settings where **MRI, CT, and PET-CT are not widely available**. Recognizing this disparity, organizations such as the **American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN)** have developed **resource-stratified guidelines** to ensure that optimal care is provided at all levels, emphasizing the need for **advanced imaging and treatment modalities whenever feasible**.

Closing the gap in **cervical cancer prevention, early detection, and treatment** requires **global efforts to expand HPV vaccination, implement effective screening strategies, and improve access to life-saving therapies**, particularly in **low-resource settings where mortality rates remain disproportionately high**

Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study



Cumulative recurrence rate by (A) parity; (B) miscarriage; (C) clinical stage; (D) treatment received; (E) lymph node metastasis; (F) chemotherapy.

HISTORY OF CERVICAL CANCER STAGING

The importance of **staging systems** in cancer management was recognized nearly a century ago, emphasizing the need for **valid, reliable, and practical classification methods**. The staging of **cervical cancer** originated from the **Radiological Sub-Commission of the Cancer Commission of the Health Organization of the League of Nations**, which identified the necessity of a **uniform system** to describe the extent of disease. This led to the **publication of Annual Reports**, documenting disease classification and staging progress.

Over time, the **International Federation of Gynaecology and Obstetrics (FIGO)** became the official body overseeing the Annual Report and **standardizing cervical cancer staging globally**. Recognizing the importance of this system, the **American Joint Committee on Cancer (AJCC)** later incorporated the **FIGO staging classification** for gynaecological cancers into its own framework. Since its initial adoption, the **FIGO staging system has undergone only a few modifications**, ensuring **consistency in disease assessment and treatment planning**. The most **significant updates** have included the incorporation of **imaging modalities such as MRI, CT, and PET-CT for more accurate disease assessment**, moving beyond purely **clinical staging to integrate modern diagnostic tools where available**.

The evolution of **cervical cancer staging** reflects a commitment to **improving prognosis, guiding treatment strategies, and ensuring standardized global reporting**, ultimately enhancing **patient outcomes and survival rates**. [4, Rank 5]

The Role Of Staging In Determining Treatment Options and Prognosis In Cervical Cancer

Cervical cancer staging is critical for treatment planning, predicting prognosis, and guiding clinical decision-making. Accurate staging helps classify the extent of the disease, ensuring that patients receive the most appropriate and effective therapy while avoiding overtreatment or undertreatment. The International Federation of Gynecology and Obstetrics (FIGO) staging system is the most widely used classification for cervical cancer and is essential in standardizing patient management globally.

How Staging Influences Treatment and Prognosis

The stage at diagnosis directly impacts treatment selection and survival outcomes:

- Early-stage disease (Stage I–IIA): Often managed with surgery (radical hysterectomy

with lymphadenectomy) or radiation therapy, with or without chemotherapy. Prognosis is excellent, with 5-year survival rates exceeding 90% in Stage IA and around 80-85% in Stage IB.

- Locally advanced disease (Stage IIB–IVA): Treated primarily with chemoradiotherapy (concurrent radiation and cisplatin-based chemotherapy). The 5-year survival rate decreases to 50–60% in Stage IIIB.
- Metastatic disease (Stage IVB): Requires palliative chemotherapy, targeted therapy, or immunotherapy to improve quality of life, but prognosis remains poor, with a 5-year survival rate of less than 20%.



FIGO STAGING SYSTEM AND ITS CLINICAL RELEVANCE

The FIGO 2018 staging system integrates clinical examination, imaging (MRI, CT, PET-CT), and histopathology to enhance accuracy in disease assessment. The stages are classified as follows:

Stage I: Cancer is confined to the cervix.

IA1 & IA2: Microscopic disease (≤5 mm invasion).

IB1 & IB2: Clinically visible tumor <4 cm.

IB3: Tumor ≥4 cm.

Stage II: Cancer extends beyond the cervix but not to the pelvic wall or lower third of the vagina.

IIA1 & IIA2: No parametrial invasion.

IIB: Parametrial invasion present.

Stage III: Cancer spreads to the pelvic wall, lower third of the vagina, or causes kidney dysfunction.

IIIA: Involves lower vagina.

IIIB: Pelvic wall invasion or hydronephrosis.

IIIC: Lymph node metastasis (pelvic or para-aortic).

Stage IV: Cancer extends beyond the pelvis.

IVA: Involvement of bladder/rectum.

IVB: Distant metastases.

Accurate FIGO staging ensures that cervical cancer patients receive personalized, evidence-based care, improving survival outcomes and quality of life.



SIGNS AND SYMPTOMS OF CERVICAL CANCER

Cervical cancer is often **asymptomatic in its early stages**, making regular screening (Pap smear and HPV testing) crucial for early detection. As the disease progresses, symptoms become more noticeable and may indicate **advanced or invasive disease**.

Early-Stage Symptoms:

1. Abnormal Vaginal Bleeding

The most common early symptom, including:

- Postcoital bleeding (after sexual intercourse).
- Intermenstrual bleeding (between periods).
- Postmenopausal bleeding.



2. Unusual Vaginal Discharge

May be **watery, pale, bloody, or foul-smelling** due to infection or necrosis of cancerous tissue.

3. Pelvic Pain or Discomfort

Persistent dull pain or cramping in the lower abdomen or pelvis, not related to menstruation.

4. Pain During Intercourse (Dyspareunia)

Due to irritation or involvement of vaginal tissues.

Advanced-Stage Symptoms:

As cervical cancer spreads to nearby tissues and organs, symptoms may become more severe, including:

1. **Severe Pelvic and Back Pain**
   Often due to **nerve involvement or tumour pressure** on surrounding structures.
2. **Leg Swelling (Lymphedema)**
   Caused by **lymphatic obstruction** from tumour spread to pelvic lymph nodes.
3. **Difficulty Urinating or Blood in Urin (Haematuria)**
   Indicates **bladder invasion** by the tumour.
4. **Bowel Changes (Constipation or Blood in Stool)**
   Suggests **rectal involvement**.
5. **Fatigue and Unexplained Weight Loss**
   A sign of **advanced disease and systemic impact**.
6. **Loss of Appetite and Generalized Weakness**
   Often due to cancer-related metabolic changes.
7. **Fistula Formation (Late-Stage)**
   Abnormal connections between the cervix and nearby organs, leading to continuous **leakage of urine (vesicovaginal fistula) or stool (rectovaginal fistula) through the vagina**.

GUIDELINES FOR CERVICAL CANCER SCREENING AND STAGING

Cervical cancer remains a clinically staged disease, primarily due to limited access to advanced surgical and radiographic expertise in resource-limited settings where its burden is highest. While global efforts are underway to expand access to imaging and surgical modalities, staging continues to rely on clinical examination and fundamental diagnostic procedures. These include palpation, inspection, colposcopy, endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, and X-ray assessment of the lungs and skeleton.

According to the FIGO staging system, a microscopic lesion measuring ≤3 mm deep (Stage IA1) or 3–5 mm deep (Stage IA2), or a visible tumor confined to the cervix measuring ≤4 cm (Stage IB1), defines early-stage disease. However, inconsistencies between clinical and surgical staging, particularly in Stage IB and Stage II cancers, often lead to misclassification and suboptimal treatment strategies. Tumor size is a critical prognostic factor, yet its accurate assessment remains a challenge, particularly in advanced-stage disease, where precise measurement is essential for determining appropriate therapy.

While cross-sectional imaging (MRI, CT, and PET-CT) is not universally endorsed for clinical staging due to cost and accessibility barriers, it is highly recommended where available for assessing tumor extent, lymph node involvement, and treatment planning. If nodal metastases are detected, documentation should specify whether they were identified through pathologic biopsy or radiologic imaging. However, pathologic findings cannot alter the clinical stage, though they play a pivotal role in optimizing treatment decisions.

A major limitation of the current clinical staging system is its exclusion of lymph node involvement, despite its profound impact on survival outcomes. Regional lymph nodes include the parametrial, obturator, internal and external iliac, common iliac, and presacral nodes, while para-aortic nodes are classified as metastatic. Research indicates that some patients with para-aortic metastases can still achieve long-term survival, though their prognosis remains inferior to those with pelvic-only nodal involvement. Additionally, nearly all patients with para-aortic disease exhibit PET-positive pelvic lymph nodes, highlighting the value of advanced imaging in staging and treatment optimization.

To enhance diagnostic precision and treatment effectiveness, global health initiatives must prioritize expanding access to HPV vaccination, implementing standardized screening protocols, and improving resource-stratified staging approaches. Integrating modern diagnostic techniques with clinical staging can bridge the gap between early detection and effective management, ultimately reducing the global cervical cancer mortality burden. [3, Rank 5]

THE ROLE OF ULTRASOUND IN DIAGNOSIS OF CERVICAL CANCER

Ultrasound (US) has emerged as a pivotal imaging modality in the diagnosis and evaluation of cervical cancer, particularly in settings where access to advanced imaging technologies is limited. Since the introduction of real-time ultrasonography, US has been widely used as a first-line imaging tool in the assessment of various gynaecological disorders. Although magnetic resonance imaging (MRI) is regarded as the gold standard for detecting, characterizing, and staging cervical cancer—particularly in industrialized nations—there has been a growing body of evidence supporting the use of ultrasound as a reliable alternative. Over the past two decades, the global acceptance and utilization of transvaginal and transrectal ultrasound in cervical cancer diagnosis have increased substantially.

Recent prospective studies have reported diagnostic accuracies of ultrasound that are

comparable to MRI, with one notable American multicentre study involving women with early-stage cervical cancer demonstrating a 96% tumour detection accuracy, with sensitivity and specificity rates of 90% and 97%, respectively.



One of the primary advantages of ultrasound lies in its practicality—it is fast, non-invasive, widely accessible, cost-effective, and requires minimal patient preparation. These attributes make it particularly advantageous in low- and middle-income countries, where the availability of MRI is often limited due to economic and infrastructural constraints. Transvaginal and transrectal ultrasound probes, when positioned in close proximity to the cervix, provide high-resolution, real-time imaging that is capable of detecting even small neoplastic lesions. Typically, cervical cancers appear on ultrasound as solid hypoechoic masses relative to the surrounding cervical stroma, although in rare cases, lesions may present as isoechoic or hyperechoic. This variation in echogenicity has been suggested to correlate with different histologic subtypes of cervical cancer, potentially offering additional diagnostic insights.Another significant benefit of ultrasound, particularly intracavitary ultrasound, is the capacity to perform dynamic assessments of tissue compressibility in real time. Malignant tumours of the cervix generally exhibit relative no compressibility compared to the normal cervical tissue, a feature that further aids in distinguishing pathological areas from normal anatomy during examination. This dynamic evaluation, combined with detailed morphological assessment, enhances the diagnostic confidence of ultrasound in clinical practice. In conclusion, while MRI remains the benchmark for comprehensive staging, ultrasound offers a highly valuable, accessible, and effective imaging alternative—especially in resource-limited environments—cementing its role in the modern diagnostic pathway for cervical cancer.

THE DIFFERENCE BETWEEN TRADITIONAL SCREENING METHODS AND LATEST SCREENING GUIDELINES FOR CERVICAL CANCER

Traditional screening methods with annual provider-based cervical collection and cytology drastically lowered the incidence of cervical cancer in the United States and other developed nations. Over the last 20 years, understanding of the pathogenesis of HPV infection in causing cervical cancer as well as the increased availability of commercial HPV tests has led to changes in screening recommendations. For decades, women were told they needed annual Pap smear testing; however, the U.S. Preventive Services Task Force, the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American College of Obstetrics and Gynaecology (ACOG) all agreed on consistent recommendations based on what trials had shown regarding the natural history of cervical cancer: cytology screening every three years for women aged 21–65, with the option for women aged 30–65 to add the HPV test with the Pap test (co-test) and extend screening intervals to every five years.

However, several US women ages 21 to 65 reported they had not been screened for cervical cancer in the last 5 years. Screening was particularly low among uninsured women, immigrant women, and women without a usual source of healthcare. Most concerning, there was a statistically significant decline in Pap testing among women aged 21–65 from 2000–2019. This finding was further substantiated using healthcare claims data and again showed a decline for all age groups. Clearly efforts are needed to reach rarely or never-screened women as well as understand this declining trend in screening.

THE IMPORTANCE OF DIAGNOSIS OF CERVICAL CANCER

Early diagnosis of cervical cancer is crucial, as the disease is often asymptomatic in its initial stages. When symptoms do appear, they may include increased vaginal discharge, post-coital bleeding, or intermittent spotting. Screening typically involves cytology (Pap smear) and human papillomavirus (HPV) testing, while a definitive diagnosis is made through colposcopy-guided biopsy. In cases where depth of invasion must be assessed—particularly in early-stage disease—cervical conization is recommended to evaluate microscopic stromal infiltration.

According to the International Federation of Gynaecology and Obstetrics (FIGO) staging system, Stage IA cervical cancer is not visible to the naked eye and is identified microscopically. Stage IA1 involves stromal invasion ≤3.0 mm,

and Stage IA2 involves invasion >3.0 mm but ≤5.0 mm, with both stages requiring a horizontal spread of ≤7.0 mm. These distinctions are determined via pathological assessment following cervical conization. After diagnosis, a series of baseline investigations are typically conducted, including blood tests (complete blood count and biochemistry to assess liver and kidney function), urine analysis, chest X-ray, and echocardiography to evaluate overall patient health and fitness for treatment.

The evolution from Pap-only to HPV-based screening represents a major advancement in cervical cancer prevention in the U.S. The newer guidelines focus on starting later, testing less frequently, and using more sensitive methods, aligning with better outcomes, cost-effectiveness, and reduced patient anxiety. As primary HPV testing becomes more available, it is poised to become the new standard for cervical cancer screening.

While FIGO staging primarily relies on clinical examination methods such as colposcopy, punch biopsy, and cervical conization—and includes cystoscopy and colonoscopy for suspected bladder or bowel invasion—imaging techniques can provide valuable supplementary information. Although CT, MRI, PET, and PET/CT are not officially included in FIGO's staging criteria, they are often used selectively to guide treatment planning, especially in advanced cases. Cystoscopy and colonoscopy are particularly important in patients with Stage IB2 or higher disease, where direct extension into the bladder or rectum is suspected.

In addition to imaging and histopathological evaluation, tumour markers such as squamous cell carcinoma (SCC) antigen play an important role. SCC antigen levels measured before treatment can reflect tumour stage, size, depth of cervical invasion, lymph vascular space involvement, lymph node metastasis, and overall prognosis. These markers are also useful for monitoring disease status during follow-up. [9, Rank 3]

DIAGNOSIS OF METASTATIC CERVICAL CANCER

Cervical cancer remains one of the most prevalent malignancies affecting women globally, with a significant proportion of patients presenting with or eventually developing **metastatic disease**, which is associated with poor clinical outcomes. Metastasis in cervical cancer typically occurs via **hematogenous** or **lymphatic** routes, each with distinct prognostic implications.

Notably, patients with **hematogenous spread** (e.g., to lungs, liver, bones, or brain) tend to have a **worse prognosis** and higher risk of mortality than those with purely lymphatic metastases.

Diagnostic Tools

Accurate staging and detection of distant metastases are crucial in guiding treatment decisions. The most effective imaging modalities include:

- **Fluorodeoxyglucose positron emission tomography (FDG-PET)** and **PET/CT**: Highly sensitive for detecting distant and occult metastatic sites.
- **MRI** and **CT scans**: Often used in conjunction for evaluating local invasion and regional lymph node involvement.
- **Histologic confirmation**: May be necessary in ambiguous cases or to guide individualized treatment.

According to the **AJCC and FIGO staging systems**, cervical cancer patients presenting with **M1 disease** (e.g., metastases to supraclavicular, mediastinal, or para-aortic lymph nodes; lung, liver, bone, or brain; or peritoneal spread) are classified as having **metastatic cervical cancer**, whether at initial diagnosis or due to persistent/recurrent disease outside the pelvis.

Patterns of Metastasis and Management Strategies

- **Lymphatic Metastasis**:
  - Typically involves **para-aortic or supra-clavicular lymph nodes**.
  - Best managed with **concurrent chemoradiotherapy (CCRT)** followed by **systemic chemotherapy**.
  - These cases generally have **better survival outcomes** than hematogenous spread.
- **Hematogenous Metastasis**:
  - Common sites: **Lungs, bones, liver, and brain**.
  - **Lung Metastasis**:
    - ❖ May respond to **chemotherapy**.
    - ❖ Surgical resection or metastasectomy can be considered in selected cases with isolated, resectable lesions.
  - **Bone Metastasis**:
    - ❖ Requires a combination of **chemotherapy** and **palliative radiotherapy** to relieve pain and prevent skeletal-related events.
  - **Brain Metastasis**:
    - ❖ **Solitary lesions**: Best managed with **craniotomy** or **stereotactic radiosurgery**, followed by radiotherapy.
    - ❖ **Multiple lesions**: Treated with **systemic chemotherapy** and **palliative whole-brain radiation**.

Prognosis and Survival

- Approximately **13%** of cervical cancer cases are diagnosed at an **advanced or metastatic stage**.
- The **5-year survival rate** is:
  - **16.5%** for metastatic disease.
  - Compared to **91.5%** for localized disease.
- **Median survival** for metastatic cervical cancer remains poor, ranging from **8 to 13 months**, underscoring the need for more effective systemic therapies and individualized care strategies.
- The **lack of a standard treatment protocol** is due to the **heterogeneous nature of metastatic disease**, which necessitates a **multimodal and patient-specific approach**.

MORTALITY RATES AND DISPARITIES IN CERVICAL CANCER CARE

Cervical cancer mortality rates in the United States highlight notable disparities based on geographic location and race. Women living in **rural areas** experience higher death rates compared to those in **urban** settings. According to national cancer registry data covering 97% of the U.S. population, the **age-adjusted mortality rate** was **2.7 per 100,000** for rural women, versus **2.2 per 100,000** for women in large metropolitan areas.

Disparities are also evident across racial groups, with **Black women facing higher mortality rates** than White women. Researchers suggest that factors contributing to these differences may include **variations in access to care**, **treatment adherence**, and **socioeconomic status**.

Recent studies have shown that cervical cancer patients who are **older**, have **larger tumours**, or come from **lower-income households** are less likely to receive standard-of-care treatment. Additionally, patients treated at **low-volume hospitals** and those with **higher comorbidity scores** are also at risk for receiving non-adherent care.

A California-based study of patients with Stage IB–IIA cervical cancer found that only **47% received care aligned with National Comprehensive Cancer Network (NCCN) guidelines**. Factors associated with lower adherence included lower socioeconomic status, older age at diagnosis, larger tumour size, and hospital volume. Interestingly, in this study, **race was not independently associated with adherence to treatment guidelines**.

However, findings from a Florida study pointed out that **late-stage diagnosis and under-treatment** were key contributors to **racial, ethnic, and socioeconomic disparities** in survival outcomes for cervical cancer patients. [8, Rank 2]

World age-standardised incidence and mortality rate for cervical cancer, estimates for 2018



TREATMENT MODALITIES FOR CERVICAL CANCER IN PRIMARY CARE

The management of cervical cancer, particularly in its early stages, is guided by the extent of disease determined through clinical staging. Primary care plays a crucial role in recognizing early signs, guiding patients through screening, and coordinating timely referrals for appropriate treatment. The main treatment modalities include surgery, radiation therapy, and chemoradiation, with decisions tailored according to stage, fertility desires, and patient comorbidities.

Early-Stage Disease (Stage IA1)

Definition:

Stage IA1 cervical cancer is characterized by microscopic disease with stromal invasion ≤3.0 mm in depth and a horizontal spread ≤7.0 mm. The tumour is not visible on imaging or clinical examination and is typically diagnosed via histopathological assessment following cervical conization.

- **Primary Options**:
  Conization or simple hysterectomy.
- **Fertility-Sparing Approach**:
  Patients with no lymph vascular space invasion (LVSI) and negative resection margins post-conization may be observed.
- **If Margins or LVSI Are Present**:
  Options include repeat conization, simple hysterectomy, or type II radical hysterectomy with pelvic lymphadenectomy.
- **For Fertility Preservation**:
  Radical trachelectomy with pelvic lymphadenectomy or conization/simple trachelectomy may be considered.

Stage IA2 Disease

Definition:

Stage IA2 cervical cancer is defined as microscopic stromal invasion >3.0 mm but ≤5.0 mm in depth and a horizontal spread ≤7.0 mm, with no visible tumour on clinical Examination or imaging. Like IA1, diagnosis is based on histopathology, usually following cervical conization.

- **Preferred Treatment**:
  Radical hysterectomy with pelvic lymph node dissection.

- **Alternative for Inoperable Patients**: Pelvic radiation therapy.
- **Fertility-Preserving Option**: Radical trachelectomy with pelvic lymphadenectomy.
- **Surgical Approach**: Minimally invasive methods (laparoscopic or robotic) and nerve-sparing radical hysterectomy may be considered for suitable candidates.

Stages IB1 and IIA1

Definition:

Stage IB1: Clinically visible lesions confined to the cervix, measuring ≤4 cm in greatest dimension.

Stage IIA1: Tumour extends beyond the uterus but not to the pelvic wall or lower third of the vagina, with maximum tumor size ≤4 cm and no parametrial invasion.

- **Standard Treatment**: Radical hysterectomy with pelvic lymph node dissection, with or without para-aortic sampling.
- **Fertility-Preserving Option**: Radical trachelectomy and pelvic lymph node dissection for early-stage disease.
- **Adjuvant Radiation Therapy**: Indicated if two or more intermediate-risk factors are present—tumour >4 cm, deep stromal invasion, and LVSI.

Stages IB2 to IIA2

Definition:

Stage IB2: Clinically visible cervical tumour >4 cm in greatest dimension, confined to the cervix.

Stage IIA2: Tumour extends beyond the cervix to the upper two-thirds of the vagina, >4 cm in size, without parametrial involvement.

- **Primary Option**: Concurrent chemoradiotherapy with cisplatin.
- **Surgical Alternative**: Radical hysterectomy followed by tailored adjuvant therapy (radiation or CCRT).
- **Neoadjuvant Chemotherapy**: May improve 5-year survival, based on retrospective data.

HIGH-RISK PATIENTS POST-SURGERY

- Criteria: Positive margins, lymph node involvement, or parametrial invasion.
- Recommended Therapy: Adjuvant concurrent chemoradiotherapy (CCRT).
- Alternative: In select cases with extensive lymphadenectomy, chemotherapy alone or observation maybe considered, omitting radiation.

Advanced Stages (IIB to IVA)

Definition:

- **Stage IIB**: Tumour with parametrial involvement but not extending to the pelvic to the pelvic wall.
- **Stage III–IVA**: Involvement of the lower third of the vagina, pelvic wall, adjacent organs (e.g., bladder or rectum), or hydronephrosis indicating ureteral obstruction.

Nodal Assessment:

Evaluation of para-aortic lymph nodes is crucial.

- **Preferred Method**: Surgical staging via laparoscopic or extraperitoneal lymph node dissection.
- **Alternative**: Radiologic imaging (CT, MRI, PET-CT) based on institutional resources.

Treatment Plan:

- **Without Para-Aortic Involvement**: Pelvic radiation plus concurrent cisplatin-based chemotherapy.
- **With Para-Aortic Involvement**: Extended-field radiation and chemotherapy.

Cervical cancer in stages IIB to IVA is characterized by **parametrial invasion (IIB)**, extension to the **pelvic wall or lower third of the vagina (III)**, or involvement of **adjacent organs like the bladder or rectum (IVA)**. Management at these stages is primarily non-surgical and relies heavily on accurate nodal assessment and tailored radio chemotherapy.

Stage IVB and Recurrent Disease

Stage IVB cervical cancer represents distant metastatic spread beyond the pelvic region, such as to the lungs, liver, bones, or distant lymph nodes. Similarly, **recurrent disease** may appear locally in the pelvis or as distant metastases after initial treatment. The primary aim in these settings is **disease control, symptom relief, and quality-of-life preservation**.

- **Systemic Chemotherapy: Mainstay of Treatment**
  - **Platinum-based chemotherapy regimens** (typically cisplatin or carboplatin combined with paclitaxel) remain the cornerstone of treatment for metastatic or recurrent cervical cancer.
  - In selected patients, **bevacizumab**, an anti-angiogenic agent, may be added to chemotherapy to improve overall survival, based on GOG 240 trial data.
  - **Immunotherapy** (e.g., PD-1/PD-L1 inhibitors such as pembrolizumab) is an emerging option, especially in **PD-L1-positive tumors** or those with **MSI-high/dMMR** status, offering durable responses in some cases.
- **Individualized Radiation Therapy: Palliative and Symptom-Oriented**

- While not curative, radiation therapy plays an essential role in **palliative management**:
  - ❖ **Pelvic radiation** can control bleeding, pain, or obstructive symptoms due to local tumor recurrence.
  - ❖ **Focal radiation** to distant metastatic sites (e.g., bone metastases or lymphadenopathy) may provide symptom relief.

- The **decision to use radiation** should be individualized based on:
- Patient's overall performance status and life expectancy.
- Symptom burden and anatomical sites of recurrence/metastasis.
- Previous radiation history and cumulative dose constraints.

Treatment of cervical cancer in primary care requires individualized plans based on clinical staging, risk factors, and patient preferences. While surgery is preferred for early stages, chemoradiation plays a key role in locally advanced and high-risk disease. The involvement of multidisciplinary teams, including primary care, gynaecologic oncology, and radiology, is essential for improving outcomes and ensuring comprehensive care. [11, Rank 5]



FIGO GUIDELINES FOR RADIATION THERAPY FOR CERVICAL CANCER

The International Federation of Gynaecology and Obstetrics (FIGO) provides comprehensive guidance for radiation therapy in cervical cancer management. Radiation therapy plays a pivotal role, particularly in locally advanced disease, often combined with chemotherapy and brachytherapy to optimize outcomes. FIGO emphasizes modern techniques and individualized planning to maximize therapeutic efficacy while minimizing toxicity.

Radiation Therapy Planning and Delivery

- **3D Conformal Radiation Therapy (3D-CRT):**
  With the aid of 3D imaging, conformal radiation plans are created to accurately target regions at risk, including the primary tumor and involved lymphatics, while sparing normal surrounding tissues such as bowel, bladder and rectum.
- **Intensity-Modulated Radiation Therapy (IMRT)**:
  IMRT offers superior dose distribution by precisely modulating radiation intensity. It enables higher doses to tumor-bearing are-as with reduced exposure to organs at risk. Studies show IMRT offers similar survival outcomes to conventional radiation while reducing gastrointestinal and urologic toxicities, making it suitable as a primary modality.

Special Considerations in Radiation Targeting Vaginal Involvement:

- **Vaginal Involvement:**
  If the tumour extends to the lower third of the vagina, prophylactic irradiation of inguinal lymph nodes is recommended to prevent regional metastasis.
- **Parametrial Involvement and Advanced Stages**:
  For extensive disease such as stage IIIB or greater, **interstitial brachytherapy** becomes essential, particularly in cases of parametrial invasion where conventional intracavitary techniques may not deliver adequate dose.

Role of Brachytherapy

- **Intracavitary Brachytherapy**:
  A critical element in the definitive treatment of cervical cancer, brachytherapy allows direct high-dose radiation delivery to the cervix while sparing adjacent organs.
- **Interstitial Brachytherapy**:
  Necessary for irregular or bulky tumours that cannot be treated effectively by intracavitary techniques alone, particularly with parametrial extension or bulky stage IIIB disease.
- **Dose Optimization and Organ Protection**: The use of individualized central shielding techniques (e.g., coned-down fields or central blocking) helps limit radiation exposure to the small intestine, bladder, and rectum during external beam and brachytherapy.

Timing and Treatment Completion

- **Treatment Duration**:
  FIGO strongly recommends completing the entire course of radiation therapy within **8 weeks**. Pro- longed treatment durations

are associated with inferior local control and survival outcomes.

- **Avoiding Delays**:
  Once radiation is initiated, treatment interruptions or prolonged gaps must be avoided. Continuous, uninterrupted therapy ensures optimal tumour response and reduces the risk of resistance or recurrence.

FIGO's radiation therapy guidelines for cervical cancer stress precision, timeliness, and the use of advanced technologies such as IMRT and brachytherapy. These approaches are aimed at improving treatment effectiveness while minimizing toxicity, particularly for patients with advanced disease or complex tumour anatomy. Adherence to these principles ensures better clinical outcomes and improved patient quality of life. [12, Rank 3]

THE IMPACT OF OPPORTUNISTIC SCREENING FOR CERVICAL CANCER

Cervical cancer (CC) remains one of the most prevalent malignancies affecting women globally, ranking second or third among all female cancers. According to 2019 data, approximately 550,000 new cases were diagnosed, with around 270,000 resulting in death—figures that highlight the ongoing burden of this largely preventable disease. The disparity is especially evident in low- and middle-income countries, where access to preventive services such as vaccination and screening remains limited. Studies further estimate that CC ranks as the fifth leading cause of female cancer globally, with roughly 15,500 new diagnoses each year in certain regions.

Purpose and Benefits of Screening

The primary goal of cervical cancer screening is the early detection of precancerous lesions and early-stage disease to prevent progression into invasive cancer. By identifying abnormalities at a treatable stage, screening significantly reduces both incidence and mortality. Over the past five decades, nations with well-structured, cytology-based screening programs have experienced substantial declines in CC-related morbidity and mortality. Screening not only facilitates earlier treatment but also improves overall survival outcomes.

Opportunistic Screening: Strengths and Limitations

Opportunistic screening, screening performed when a woman seeks care for another reason or on a provider's discretion—can contribute to lowering CC rates but is generally less effective than organized programs. This approach tends to target younger, more health-aware populations, potentially excluding older women who are at greater risk. Moreover, its

success is highly dependent on individual participation, which is influenced by several social determinants such as education level, marital status, ethnicity, smoking habits, and psychological or logistical barriers.

Global Practices and Evolving Guidelines

Countries like Canada and the United States have historically led efforts in cervical cancer screening, with the U.S. adopting a predominantly opportunistic model. In recent years, however, there has been a shift toward incorporating organized elements into national screening strategies. The World Health Organization (WHO) and various national health bodies now advocate for population-based, organized screening programs with built-in quality assurance measures. These programs have shown to be more equitable and effective in reaching at-risk populations and improving outcomes.

Program Structure and Impact

The implementation of structured screening initiatives has been instrumental in decreasing invasive CC incidence and mortality. These programs also influence the stage at diagnosis, leading to earlier-stage detection and shifts in histological subtypes, which can inform treatment and prevention strategies. However, variability in program design and coverage continues, largely depending on available resources and political will.

Challenges and Current Screening Recommendations

Despite available methods, cervical cancer remains a major public health challenge, especially in underserved populations. In the U.S., incidence and mortality rates remain relatively high in certain demographics, with limited decline observed in recent years. Traditional guidelines recommended annual cytological (Pap) testing starting at age 18 with no upper age limit, often combined with a pelvic examination. Tools like the cytobrush are preferred for optimal sample collection. However, modern guidelines now emphasize less frequent but more sensitive testing, including HPV-based screening every 5 years starting at age 25 or 30, depending on the specific protocol.

Public Health Perspective and Survival Data

From a public health standpoint, survival data serve as a critical metric for evaluating the effectiveness of screening and treatment programs. Cancer registries are used to track trends and identify disparities in outcomes. Survival analyses allow health authorities to assess differences between screened and unscreened patients based on

sociodemographic factors, clinical presentation and hazard ratios. These data help tailor interventions to reduce inequities and enhance care delivery across populations.

INTRODUCTION TO NEUROENDOCRINE NEOPLASIAS (NENS)

Neuroendocrine carcinoma of the cervix (NECC) is a rare, highly aggressive subtype of cervical cancer, accounting for approximately 1–1.5% of all cervical malignancies. These tumours arise from neuroendocrine cells that originate from the embryonic neuroectoderm and exhibit immunohistochemical markers characteristic of endocrine cells, such as chromogranin A, synaptophysin, and CD56. NECC is classified into small cell and large cell neuroendocrine carcinomas, with small cell being the most common, while well-differentiated neuroendocrine tumours (NETs) such as typical and atypical carcinoids are extremely rare in the cervix. Compared to more common cervical cancers like squamous cell carcinoma or adenocarcinoma, NECC demonstrates a more aggressive clinical behaviour, including early lymph vascular space invasion, regional lymph node involvement, and a higher likelihood of distant metastasis, leading to a poorer 5-year overall survival rate of around 30%. Because of its rarity, there are no standardized treatment guidelines, and man-agement often mirrors protocols for small cell lung cancer, involving a multidisciplinary approach with radical surgery in early stages and platinum-based chemotherapy and/or concurrent chemoradiation for advanced disease. Diagnostic confirmation relies on histopathology and immunohistochemistry, and staging involves comprehensive imaging such as CT, MRI, or PET-CT to evaluate for spread. Given its aggressive nature and frequent late-stage presentation, early detection and timely, individualized treatment are critical to improving patient outcomes, although prognosis remains significantly worse than other cervical cancer subtypes.

THE EFFECTIVENESS OF INTERVENTIONS IN CERVICAL CANCER SCREENING

he effectiveness of interventions in cervical cancer screening (CCS) is vital in reducing the global burden of this highly preventable disease. Despite the availability of effective screening tools such as the Papanicolaou (Pap) smear and human papillomavirus (HPV) DNA testing, cervical cancer remains a significant public health issue, particularly in low- and middle-income countries where 95% of cases occur. Globally, cervical cancer is the second leading cause of cancer-related mortality among women, with incidence rates notably

increasing in developing regions. In the United States, cervical cancer ranks fourth among gynaecologic cancers, with an incidence of approximately 4.5 cases per 100,000 women. The World Health Organization (WHO) recommends regular screenings using Pap or HPV DNA tests as a critical strategy for early detection and intervention. Organized CCS programs using these methods have led to a 34%–80% reduction in both incidence and mortality in many developed countries. However, in developing regions, participation in CCS programs remains suboptimal due to various factors. These include limited knowledge about cervical cancer and screening services, health beliefs (e.g., screening is unnecessary without symptoms), fear of pain or diagnosis, embarrassment, cultural norms, preference for female healthcare providers, and logistical barriers such as cost, access, and wait times. Studies show that women who have never had a Pap test report significantly higher perceived barriers than those who have, underscoring the importance of targeted interventions. Educational initiatives, personalized reminder systems (e.g., Pap-specific letters), and community engagement strategies that address cultural sensitivity and enhance health literacy have been found to significantly improve participation rates. Interventions that eliminate misconceptions, reduce emotional and physical discomfort, and enhance the visibility and accessibility of screening services are essential. Given that lack of awareness and knowledge are among the most significant factors hindering CCS participation, public health programs must prioritize awareness campaigns, behaviour change interventions, and culturally appropriate outreach efforts to ensure higher uptake and, ultimately, reduce cervical cancer incidence and mortality globally.

THE ROLE OF NURSES IN PROVIDING PREVENTIVE HEALTHCARE SERVICES

Nurses play a **pivotal role** in delivering preventive healthcare services, especially in the early detection and prevention of diseases such as cervical cancer. Their contribution extends beyond clinical care to encompass **public education, community outreach, and data-driven intervention**.

In many developed countries, nurses trained in **early cancer detection programs** are integral to the success of national and regional **public health screening initiatives**. They work collaboratively with physicians, public health specialists, and policymakers to implement effective preventive strategies.

Key Responsibilities of Nurses in Cervical Cancer Prevention:

- **Health Education and Awareness**:
  - Provide women with clear and culturally appropriate information about cervical cancer risk factors, symptoms, and prevention methods.
  - Promote the importance of regular screening and HPV vaccination.
- **Encouraging Participation in Screening Programs**:
  - Motivate and empower women to take part in **routine cervical cancer screening**, such as **Pap smear** and **HPV testing**.
  - Address fears, misconceptions, and barriers related to screening procedures.
- **Implementation of Screening Services**:
  - Perform or assist with **Pap smear tests** and ensure proper sample collection and documentation.
  - Monitor and ensure quality control in screening procedures.
- **Data Collection and Evaluation**:
  - Maintain accurate records of screening results and follow-up care.
  - Analyze data to identify gaps in screening coverage and areas for intervention.
- **Referral and Coordination of Care**:
  - Guide women with abnormal results to appropriate healthcare services for further diagnostic procedures and early treatment.
  - Ensure continuity of care and timely access to specialists when needed.

Through these activities, nurses contribute significantly to **reducing cervical cancer morbidity and mortality**, especially when screening and preventive services are delivered in a **community-centred and equitable** manner.



PAP SMEAR TEST

Cervical cancer remains one of the most **common and deadly cancers** affecting women globally. However, it is also one of the **most preventable**, thanks to a simple and widely available screening tool—the **Pap smear (Papanicolaou test)**. This test is regarded as **one of the most effective cancer prevention strategies** ever developed.

SCREENING OF CERVICAL CANCER USING PAP SMEAR

Global Burden and Preventability

Each year, more than **500,000 women are diagnosed** with cervical cancer, and nearly **half succumb to the disease**. The variation in incidence and mortality between countries is significant—while cervical cancer is the most common cancer among women in some low-resource countries, in others it ranks as low as 10th in prevalence. This disparity is primarily attributed to the **success or absence of organized screening programs**, particularly those using the Pap smear.

Effectiveness of the Pap Smear

The Pap smear works by identifying **precancerous cellular changes** in the cervix long before cancer develops. If detected early, these abnormalities can be treated with **simple outpatient procedures**, effectively preventing the progression to cervical cancer. With early detection, the **5-year survival rate** for cervical cancer is as high as **92%**, demonstrating the life-saving potential of regular screening.

Challenges in Screening Programs

Despite its effectiveness, **visual examination of Pap smears is time-consuming, labor-intensive, and costly**. Over the past several decades, numerous attempts have been made to **automate Pap smear analysis** in order to reduce costs and increase accessibility. While the first commercial automated systems became available around the early 2000s, they have not significantly impacted the overall cost of large-scale screening programs.

Towards Global Accessibility

Innovative, cost-effective solutions for Pap smear analysis remain essential to expanding **equitable access** to screening, especially in **low- and middle-income countries** where the disease burden is highest. Studies and technological advancements in automation may help overcome current limitations, potentially enabling **affordable cervical cancer screening for all women worldwide**.

Impact of Organized Screening

The most significant reductions in cervical cancer incidence and mortality have been observed in countries with **systematic, well-**

organized Pap smear-based screening programs. These programs offer **regular testing, follow-up care, and public health education**, contributing to a marked decline in cervical cancer rates.

Advocacy around cervical health is especially relevant during national observances, including:

- Cervical Health Awareness Month (January)
- HPV Awareness Day (March 4)
- Gynaecological Cancer Awareness Month (September)
- Cervical Cancer Elimination Day (November 17)

GUIDELINES FOR PRIMARY CARE PROVIDERS: PAP SMEAR SCREENING

Overview

The **Pap smear test** is a simple, effective, and widely adopted method for detecting **precancerous and cancerous lesions** in the cervix. It involves collecting cervical cells from the **squamocolumnar junction** using a spatula or brush, smearing them on a **glass slide (25 × 50 mm)**, staining, fixing, and then examining the sample under a microscope.

Historical Background

The test was first proposed by **Dr. Papanicolaou in 1928** and gained wide medical acceptance in the 1940s. Since then, standardized screening protocols have significantly reduced cervical cancer incidence worldwide.

Screening Process

- **Cytotechnologists (Cytotec's)** are trained professionals who screen the Pap smears using light microscopy.
- A **40x magnification lens** is typically used to observe fine cellular details such as:
  - **Enlarged, irregular nuclei**
  - **Reduced cytoplasm**
  - **Coarse and irregular chromatin**
- If suspicious cells are found, the sample is reviewed by a **cytopathologist** for confirmation.

Diagnosis and Follow-Up

- **High-grade lesions**: Referred for **colposcopy** and possibly surgical removal.
- **Low-grade lesions**: Typically followed up with a **repeat Pap test** after a shorter interval than the routine **2–3 years**.

Technical Challenges

- A single slide can contain **hundreds of thousands of cells**, with **diagnostic cells being rare**.

- Initial screening is done at **10x magnification** (about 1,000 fields per slide), then suspicious areas are examined at **40x**.
- On average, it takes **5–10 minutes** to screen one slide.
- Cytotec's are recommended to screen **no more than 70 slides per day** to reduce fatigue, as they must inspect **3 image fields per second** with sustained concentration.

Role of Technology

- Advances in **digital imaging and computer displays** have led to **interactive and automated screening systems**.
- **Pre-screening systems** can identify clearly normal slides, reducing manual workload.
- Slides with potential abnormalities are still reviewed **manually for diagnostic confirmation**.

PAP SMEAR TEST: CLASSIFICATION STRATEGIES

Why Pap Smear Screening Is Done

- The main goal is to **find early cell changes** (precancerous lesions) before they turn into cervical cancer.
- Most test results (about **96%**) are **normal**.
- If something looks wrong, it's sent to a **specialist doctor (cytopathologist)** to check.

What Happens After an Abnormal Result?

- The woman is called in for more tests, like a **colposcopy** and possibly a **biopsy**.
- If a problem is found, it can be treated early—often with a small **surgical procedure** to remove the abnormal area.

Using Automated Machines for Screening

1. Prescreening Mode

- A computer checks the sample first.
- If it looks **completely normal**, it may not need to be reviewed by a person.
- This saves time and work for lab staff.

2. Parallel Screening

- Both the **machine and a human** check every sample.
- This helps **catch more problems** but can be **more expensive and time-consuming**.

How Results Are Classified: THE BETHESDA SYSTEM

Pap smear results are grouped into levels:

1. Normal
2. Minor changes
3. Low-grade lesions (may go away on their own)
4. High-grade lesions (more serious, need treatment)
5. Cancer

CERVICAL CANCER SCREENING: KEY GUIDELINES AND GLOBAL INSIGHTS

- **Global Differences in Survival and Screening**
  - Cancer survival rates vary greatly across countries.
  - Developed countries with **organized screening programs** have seen steady **declines** in cervical cancer cases and deaths.
  - In contrast, **many developing countries** have seen **rising numbers** of new cervical cancer cases due to weak screening systems.
- **The Importance of Early Detection**
  - While **HPV vaccination** helps prevent cervical cancer, **screening** is still essential especially in countries where vaccination rates are low.
  - **Early detection** of abnormal cervical cells can **prevent cancer from developing**.
- **Screening Success in Developed vs. Developing Countries**
  - Countries like the **U.S.** have **high screening rates (~83%)**, leading to major reductions in cervical cancer.
  - In many **developing countries**, screening rates are still low (**6–8%**), resulting in **higher mortality rates**.
- **HPV Testing: A Newer Screening Option**
  - Cervical cancer is strongly linked to **high-risk HPV types**.
  - **HPV testing** is recommended by the **World Health Organization (WHO)** and **European Guidelines**.
  - It is **very effective** at detecting early cervical changes, especially in **large population-based programs**.
- **Challenges in Screening Access**
  - In countries with **disorganized** or **limited resources**, many women remain unscreened.
  - Even in countries with strong healthcare systems, some women—especially those who are **uninsured, low-income, or marginalized**—don't get screened regularly.
- **Barriers to Screening**

Common reasons women avoid screening:

  - **Cost**
  - **Lack of access**
  - **Fear or anxiety**
  - **Discomfort** with the procedure
  - **Low health literacy**

- **The Way Forward**
  - Improving screening outcomes requires **comprehensive healthcare strategies**.
  - Solutions should make screening more **affordable, accessible, and culturally sensitive**.
  - The goal: ensure **more women**, especially in **high-risk areas**, benefit from early detection and prevention.

EFFECTS OF EDUCATIONAL INTERVENTIONS IN CERVICAL CANCER SCREENING

Cervical cancer is one of the most common and deadly cancers in women worldwide, especially in developing countries. It is mainly caused by the human papillomavirus (HPV), and most cases can be prevented through vaccination and regular screening. The World Health Organization considers cervical cancer a preventable disease, and elimination is possible if HPV vaccination coverage reaches 80–100% and HPV-based screening is done twice in a woman's lifetime. Studies have shown that HPV vaccines are safe and highly effective, and HPV tests are better at detecting early changes than older methods like visual inspection or Pap tests alone. However, many women still don't get screened due to social, cultural, and economic barriers, lack of awareness, or limited access to healthcare services. Educational interventions play a key role in increasing awareness, changing attitudes, and encouraging women to participate in cervical cancer screening. By raising awareness and empowering women with knowledge, health education can boost screening rates and help reduce cervical cancer incidence and death around the world.

EVOLVING CONCEPTS FOR PREVENTING CERVICAL CANCER

Pap cytology has been the **standard cervical cancer screening method** for over 50 years. It uses the **Bethesda System** for evaluation and has evolved to include **liquid-based cytology (LBC)** and **automated processes** since the 2000s. In developed countries, **nationwide Pap test programs** have helped reduce cervical cancer mortality by up to **80%**.

As scientists better understood the role of **high-risk human papillomavirus (HPV)** in causing cervical cancer, **HPV DNA testing** emerged as a **more sensitive tool** than Pap testing alone. Initially, **HPV testing** was used for **triaging women** with abnormal Pap results.

Later, it was combined with Pap testing (**co-testing**) or used with **HPV genotyping** to improve accuracy. However, using **HPV testing alone** raised concerns:

- **High false positive rates** led to unnecessary **colposcopy referrals**, causing anxiety and potential **overdiagnosis** and **overtreatment**.

Challenges in Low-Resource Settings

In **developing countries**, where **over 80% of cervical cancer cases** occur, screening programs face several obstacles:

Concerns in High-Resource Settings

In **developed countries**, repeated and widespread screening puts:

- **Financial strain** on healthcare systems
- **Mental pressure** on women participating in frequent testing

The Need for Improvement

While current screening strategies have been successful, there is a growing need for:

- **Risk-stratified screening programs** — that is, tailoring screening based on a woman's **risk profile** Balancing **cost-effectiveness**, **accuracy**, and **psychological impact** for better prevention and management



CONCLUSION

Cervical cancer is now clearly understood to be caused by **human papillomavirus (HPV)** infection. This has led to the development of **HPV testing** as an alternative or supplement to the traditional **Pap smear**.

Studies show that **combining Pap and HPV testing** improves the chances of detecting **precancerous changes**. However, replacing the Pap test with HPV testing **alone** offers only limited additional benefit at this time.

The discovery of the viral cause has also led to the development of **HPV vaccines**, which offer a powerful tool for **prevention**. In theory, **widespread global vaccination** could reduce cervical cancer to such low levels that **screening might no longer be needed**.

Unfortunately, **global vaccine coverage is still incomplete**, especially in low-resource countries.

Even with universal vaccination, it will take **decades** for the full protective effects to reach **all age groups**. Until then, **regular screening remains essential** to detect and treat cervical changes early and reduce cervical cancer deaths worldwide.

REFERENCES

1. Abdullah F, Su TT. Applying the transtheoretical model to evaluate the effect of a call–recall program in enhancing Pap smear practice:A cluster randomized trial. Prev Med. 2019

2. Abiodun OA, Olu-Abiodun OO, Sotunsa JO, Oluwole FA. Impact of health education intervention on knowledge and perception of cervical cancer and cervical screening uptake among adult women in rural communities in Nigeria. BMC Public Health. 2015

3. Armijo OS, Stiles R, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews:a comparison of the cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool:methodological research. J Eval Clin Pract. 2015

4. Austoker J, Bankhead C, Forbes LJL, et al. Interventions to promote cancer awareness and early presentation:systematic review. Br J Cancer. 2018

5. Baron RC, Rimer BK, Breslow RA, et al. Client-directed interventions to increase community demand for breast, cervical, and colorectal cancer screening:a systematic review. Am J Prev Med. 2018

6. Baron RC, Rimer BK, Coates RJ, et al. Methods for conducting systematic reviews of evidence on effectiveness and economic efficiency of interventions to increase screening for breast, cervical, and colorectal cancers. Am J Prev Med. 2017

7. Bebis HR, Nesrin Y, Tulay BD, Unal AB, Serkan D. Effect of health education about cervical cancer and papanicolaou testing on the behavior, knowledge, and beliefs of Turkish women. Int J Gynecol Cancer. 2016

8. Bleggi T, Luiz F, Werner B, et al. Cervical cancer screening program of Paraná:Cost-effective model in a developing country. Diagn Cytopathol. 2018

9. Champion VL, Springston JK, Zollinger TW, et al. Comparison of three interventions to increase mammography screening in low income African American women. Cancer Detect Prev. 2016

10. Chan CWH, Choi KC, Wong RS, et al. Examining the cervical screening behaviour of women aged 50 or above and its predicting factors:A population-based survey. Int J Environ Res Public Health. 2016

11. Coronado I, Evelyn A, Chidinma P, Aung M, Jolly PE. Increasing cervical cancer awareness and screening in Jamaica:Effectiveness of a theory-based educational intervention. Int J Environ Res Public Health. 2015

12. Daryani S, Shojaeezadeh D, Yazdani Charati J, Batebi A, Naghibi A. The effect of

education based on health belief model on women's practice about pap smear test. J Cancer Policy. 2015

13. Deeks JJ, Dinnes J, D'amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2017

14. Dehdari T, Hassani L, Hajizadeh E, et al. Effects of an educational intervention based on the protection motivation theory and implementation intentions on first and second pap test practice in Iran. Asian Pac J Cancer Prev. 2019

15. Esin MN, Bulduk S, Ardic A. Beliefs about cervical cancer screening among Turkish married women. J Cancer Edu. 2016

16. Fernández E, Maria E, Cardenas TM. Cervical cancer screening among Latinas recently immigrated to the United States. Prev Med. 2015

17. Gahremani-Nasab P, Shahnazi M, Farshbaf-Khalili A, Ganbari S. Factors related to cervical cancer screening among women referring to health centers in Tabriz, Iran 2019

18. Gana GJ, Oche MO, Ango JT, Raji MO, Okafoagu NC. Effect of an educational program on awareness
of cervical cancer and uptake of Pap smear among market women in Niger State, North Central Nigeria. J Public Health Epidemiol. 2016

19. Ghahremani L, Harami ZK, Kaveh MH, Keshavarzi S. Investigation of the role of training health volunteers in promoting pap smear test use among Iranian women based on the protection motivation theory. Asian Pac J Cancer Prev. 2016

20. Group IARC Working. Human papilloma viruses, IARC Monograph on the evaluation of carcinogenic risks to humans. Lyon, France: International Agency for Research on Cancer; 2015

21. Guvenc G, Akyu A, Açikel CH. Health belief model scale for cervical cancer and Pap smear test:psychometric testing. J Adv Nurs. 2018

22. Guvenc G, Akyuz A, Yenen MC. Effectiveness of nursing interventions to increase pap smear test screening. Res Nurs Health. 2017

23. Hanaa AA Y, EL Sayed HA. Effect of self learning package based on health belief model on cervical cancer prevention among female university students. J Nurs Health Sci. 2015

24. Health World health organization reproductive, diseases, world health organization chronic, and promotion, health. Comprehensive cervical cancer control:a guide to essential practice: World Health Organization. 2016

25. Hou Su I. Stage of adoption and impact of direct-mail communications with and without phone intervention on Chinese women's

cervical smear screening behavior. Prev Med. 2016

26. Jibaja W, Maria L, Volk RJ, et al. Tailored messages for breast and cervical cancer screening of low-income and minority women using medical records data. Patient Educ Couns. 2019

27. Johnson CE, Mues KE, Mayne SL, Kiblawi AN. Cervical cancer screening among immigrants and
ethnic minorities:a systematic review using the health belief model. J Low Genit Tract Dis. 2018

28. Karimy M, Gallali M, Niknami SH, Aminshokravi F, Tavafian SS. The effect of health education program based on health belief model on the performance of Pap smear test among women referring to health care centers in Zarandieh. J Jahrom Univ Med Sci. 2018

29. Katz ML, Tatum CM, Degraffinreid CR, Dickinson S, Paskett ED. Do cervical cancer screening rates increase in association with an intervention designed to increase mammography usage? J Womens Health. 2017

30. Krok S, Jessica L, Oliveri JM, et al. Evaluating the stage of change model to a cervical cancer screening intervention among Ohio Appalachian women. Women Health. 2016

31. American Cancer Society. (2023). *Cervical cancer: Early detection, diagnosis, and staging.* https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging.html

32. American Society of Clinical Oncology (ASCO). (2021). *Cervical cancer guidelines.* https://www.asco.org

33. World Health Organization. (2021). *WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention.* https://www.who.int/publications/i/item/9789240030824

34. Centers for Disease Control and Prevention (CDC). (2023). *HPV vaccination recommendations.* https://www.cdc.gov/hpv/hcp/vaccine.html.